Omni Bio Pharmaceutical — Biotech Showcase 2011
22 slides from Omni Bio Pharmaceutical's conference presentation, Jan 11, 2011

Slide 1: Omni Bio Pharmaceutical, Inc - Biotech Showcase
January 11, 2011 OTCBB: OMBP Omni Bio Pharmaceutical, Inc Biotech Showcase San Francisco, CA

Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

Slide 3: Investor Highlights
Investor Highlights 3 IP Distribution Acceptance Innovation Broad intellectual property position in major markets - - Diabetes, influenza, transplant rejection, biohazards FDA approved pharmaceutical applied to new and large markets Outsourced business model requiring low overhead Capital requiremen

Slide 4: Mission
Mission 4 Applying approved and safe products for the treatment of immunological conditions such as Type 1 and 2 diabetes, acute or chronic transplant rejection and drug resistant bacterial and viral infection Bacterial disorders Viral disorders Graft vs. host disease and transplant rejection Type 1

Slide 5: The Opportunity
The Opportunity 5 When How What To develop, patent, and commercialize previously approved (FDA) drugs in new patented indications with large market opportunities. An existing FDA approval for an existing drug means there are limited safety issues and a significantly reduced time to market for new in

Slide 6: The Opportunity: Alpha-1-Antitrypsin (AAT)
The Opportunity: Alpha-1-Antitrypsin (AAT) 6 Core Technology Advantages Anti-migratory Anti-complement Prevents maturation of antigen presentation Induces T-regulatory cells Inhibits responses to inflammatory cytokine Increases production of anti-inflammatory molecules Inhibits destructive enzymes s

Slide 7: Target Populations
2M in US including adults 15-18,000 Type 1 juvenile diabetics diagnosed in US each year (40- 50/day) No alternative to insulin therapy 50,000 pre-Type 1 diabetics may benefit 24M in US Treatment of patients failing current therapy and/or high risk of cardiovascular complications is approximately 2.4

Slide 8: IP Portfolio
IP Portfolio 8 Licensee of three patent portfolios from the University of Colorado-Denver comprising 3 issued and 19 filed patents Two issued patents and additional patent applications for the treatment of viral diseases including Influenza and HIV-1 Patent applications for the treatment of graft vs

Slide 9: Sponsored Research & License Agreements
Composition of matter and methods of use for AAT-based treatment of: Sub-license components of the IP portfolio to one or more producers of AAT, many of whom are major pharmaceutical companies An affiliate of the University of Colorado owns approximately 5% of Omni's common stock 9 Type 1 and Type 2

Slide 10: Research & Development Pipeline
10 Research & Development Pipeline Diabetes Flu Tuberculosis Transplant Rejection Anthrax AAT Laboratory In-VitroProof-of-Concept Studies Proof-of-ConceptAnimal Studies FDA Approved Human Clinical Trial (IND)

Slide 11: FDA Approved Human Clinical Trial
FDA Approved Human Clinical Trial Initial patients have been infused in Phase 1/2 human clinical trial of AAT in recently diagnosed Type 1 diabetics Preventing the destruction of insulin-producing islet (beta) cells Barbara Davis Center for Childhood Diabetes at the University of Colorado Hospital,

Slide 12: The AAT Impact on Human Islets
12 Presence of IL-1b/IFNg + Vehicle Presence of IL-1b/IFNg + AAT r Human Islets: Effect of cytokine induced toxicity and protection by AAT The AAT Impact on Human Islets Disintegrating, dying islets, as takes place in vivo by immune attack Intact, living islets protected by AAT during an immune atta

Slide 13: Influenza
Influenza 13 In the U.S. each year: - - 10-20% of population infected (30-60 million people) Children and the elderly are at risk groups 114,000 hospitalizations - - 36,000 deaths - - Economic burden= $3-15 billion

Slide 14: AAT Inhibits Flu Production in Infected Cells
100% 80% 60% 40% 20% AAT Inhibits Flu Production in Infected Cells 14

Slide 15: AAT: Protects Cells from Flu Infection
Flu alone Flu + AAT 15 AAT: Protects Cells from Flu Infection

Slide 16: AAT Impact on Influenza
16 AAT Impact on Influenza Both a treatment and prophylactic product Potentially broad spectrum treatment for influenza including "bird Flu," "swine Flu (H1N1)," and "weaponized" Flu Impervious to mutation-induced resistance Compatible with existing Flu treatments and immunization Inhaled delivery p

Slide 17: Balance Sheet
17 Balance Sheet ($ in Millions) Sept. 30, 2010 March 31, 2010 Cash 0.7 1.8 Current Assets 1.2 1.8 Total Assets 1.2 1.9 Current Liabilities 0.1 0.2 Total Stockholders' Equity 1.1 1.7 Total Liabilities and Stockholders' Equity 1.2 1.9

Slide 18: About Omni Bio
18 OTC BB: OMBP Fiscal year end: March 31 Outstanding shares at Dec 31, 2010: 29.0 million Common Stock & Equivs. O/S at Dec 31, 2010: 39.6 million Closing Stock price at January 6, 2011: $4.00 52 week range: $2.99 - $12.00 About Omni Bio

Slide 19: Management
Management Chief Executive Officer-Charles A. Dinarello, MD - - Member of the National Academy of Sciences - - World's fourth most-cited scientist for 20 years (1982-2003 Institute for Scientific Information ) - - Numerous international awards : - - 2008 Sheik Hamdan Prize (United Arab Emirates) - -

Slide 20: Principal Investigator at the University of Colorado-Denver
Principal Investigator at the University of Colorado-Denver, Anschutz Medical Campus Dr. Leland Shapiro, MD, FACP -Associate Professor of Medicine -Certified by American Board of Internal Medicine -Broadly Published Researcher on alternative uses of Alpha-1 antitrypsin 20

Slide 21: Investment Opportunity
Investment Opportunity Investment Opportunity World-class scientific leadership and strong management team Proven pharmaceutical applied to new and larger markets Phase 1/2 human clinical trial for Type 1 diabetes now in progress .. Three patents issued and 19 patents pending Sponsored research and

Slide 22: Thank you for your interest
Thank you for your interest Thank you for your interest 22
Source: SEC EDGAR · 8-K filed Jan 11, 2011
More decks from Omni Bio Pharmaceutical Inc
Investor Presentation (September 2014)27 slides · Sep 11, 2014
Investor Presentation (June 2014)26 slides · Jun 3, 2014
Investor Presentation (September 2013)24 slides · Sep 9, 2013
Investor Presentation (July 2013)27 slides · Jul 2, 2013
Investor Presentation (February 2013)20 slides · Feb 12, 2013
Investor Presentation (March 2012)25 slides · Mar 20, 2012